Pressure BioSciences, Inc. to Present at the 13th Annual BIO CEO & Investor Conference

SOUTH EASTON, Mass., Feb. 14, 2011 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (Nasdaq:PBIO) ("PBI") today announced that it will present at the 13th Annual BIO CEO & Investor Conference being held at the Waldorf-Astoria Hotel in New York City from February 14-15, 2011. Mr. Richard T. Schumacher, PBI President and CEO, will provide a corporate overview at 4pm EST on Monday, February 14th. 

About the BIO CEO & Investor Conference

The BIO CEO & Investor Conference is the largest independent investor conference focused on publicly traded biotech companies. BIO One-on-One Partnering provides an opportunity to arrange meetings among investors, companies, and industry BD, licensing, and therapeutic franchise heads.

 About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (PBI) is a NASDAQ Capital Markets listed company focused on the development and sale of instrumentation and consumables based on a novel, enabling technology platform called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 24 issued patents covering multiple applications of PCT in the life sciences field, including genomic and proteomic sample preparation, pathogen inactivation, the control of chemical reactions, immunodiagnostics, and protein purification. PBI currently focuses its efforts on the development and sale of PCT-enhanced bio-molecule extraction and enzymatic digestion products designed specifically for the mass spectrometry marketplace, as well as sample preparation products for biomarker discovery, soil and plant biology, forensics, histology, and counter-bioterror applications. 

Forward Looking Statements

Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2009, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.  

Visit us at our website http://www.pressurebiosciences.com

CONTACT:  Investor Contacts:
          Richard T. Schumacher, President & CEO
          R. Wayne Fritzsche, Chairman
          (508) 230-1828 (T)

Released February 14, 2011